N. Shomron (1), N. Hamasaki-Katagiri (2), R. Hunt (2), K. Hershko (2), E. Pommier (2), S. Geetha (2), A. Blaisdell (2), A. Marple (3), I. Roma (3), J. Newell (2), C. Allen (2), S. Friedman (4), C. Kimchi-Sarfaty (2)
(1) Department of Cell and Developmental Biology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; (2) Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, USA; (3) Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA; (4) Division of Liver Diseases, Mount Sinai School of Medicine, New York, New York, USA
Although ADAMTS13, the von Willebrand factor (VWF)-cleaving protease, is expressed in a range of tissues, the physiological significance of tissue-specific ADAMTS13 alternative splicing isoforms have yet to be clarified. Screening a panel of human tissues and cell lines revealed a spliced ADAMTS13 transcript in hepatic stellate cells and a hepatoma cell line that retains the 25th intron. A nonsense codon within the intron truncates the protease, which gains 64 novel amino acids in lieu of both CUB domains. This isoform, while retaining VWF-cleaving capability, accumulates intracellularly and its biological inaccessibility may prevent its participation in regulating haemostasis and other physiologic functions.
ADAMTS13, TTP, alternative splicing, intron retention, CUB domain
Reinhard Schneppenheim 1, Johanna A. Kremer Hovinga2 , Tim Becker3 , Ulrich Budde4 , Diana Karpman 5, Wolfgang Brockhaus6 , Ingrid Hrachovinová 7, Bartosz Korczowski8 , Florian Oyen 1 , Šimon Rittich7 , Johannes von Rosen 9, Geir E. Tjønnfjord10, J
Thromb Haemost 2006 96 1: 3-6
Manfred Rieger 1*, Silvia Ferrari 1*, Johanna A. Kremer Hovinga 2 , Christian Konetschny 1 , Andrea Herzog 1 , Letizia Koller 1 , Alfred Weber 3 , Giuseppe Remuzzi 4 , Michael Dockal 1 , Barbara Plaimauer 1 , Friedrich Scheiflinger 1
Thromb Haemost 2006 95 2: 212-220
K. Kentouche (1), A. Voigt (1), E. Schleussner (2), R. Schneppenheim (3), U. Budde (4), J. F. Beck (1), E. Stefańska-Windyga (5), J. Windyga (5)
Hämostaseologie 2013 33 2: 144-148
Patients receiving oral anticoagulants should be carefully managed to minimize the risk of bleeding...
Acquired haemophilia A (AHA) is a rare but often severe bleeding disorder caused by ...
Section III " Vitamin K antagonists in heart disease: Current status and perspectives" of...